Product Brochure

Your Product Innovation Begins Here: Booth 4555

Overview

EffePharm will showcase innovative anti-aging solutions, including UthPeak™ reduced NMN (NMNH), the first Self-GRAS approved, US patent-pending reduced NMN. Backed by the largest and longest clinical trial, demonstrating an impressive 5-year age reversal.

In addition to NMNH, we will present other premium anti-aging offerings such as MitoAge™ Urolithin A, along with exciting new innovations in our weight management sector.

Discover our clinically proven liposomal products designed for enhanced absorption and efficacy, featuring LipoAvail™ liposomal NAD+ and LipoAvail™ liposomal glutathione.

This content is provided by Effepharm Ltd, and any views and opinions expressed do not necessarily reflect those of NutraIngredients.com

Download Now

Latest Content

NMN supplementation proved to mitigate radiotherapy-induced damages

Paid for and content provided by Effepharm Ltd

Scientific study validates NMN’s efficacy in alleviating intestinal damages caused by radiotherapy through reducing alterations to gut bacteria composition and function.

NMN New Clinical Finding: Obvious NAD(H) Level Increase

Paid for and content provided by Effepharm Ltd

With 7.3% CAGR, The "Nicotinamide Mononucleotide (NMN) Market" size is expected to grow from 194.2 million USD In 2020, to reach 296.5 Million USD by 2026.”

Related Resources

Clinically Proven LipoAvail® NAD Better Absorption

24-Sep-2025

Content provided by Effepharm Ltd

White Paper

Liposomal technology encapsulates active ingredients within liposomes, mimicking intestinal cell membranes for improved absorption and efficacy.

Booth L05 for Clinically Backed NMN & Liposomal VC

27-Aug-2025